News headlines about Qiagen (NASDAQ:QGEN) have been trending positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Qiagen earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.5890105083716 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Qiagen’s (QGEN) “Buy” Rating Reiterated at Commerzbank (americanbankingnews.com)
- Brokerages Anticipate Qiagen NV (QGEN) Will Post Quarterly Sales of $392.98 Million (americanbankingnews.com)
- QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis … – PR Newswire (press release) (prnewswire.com)
- QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems (finance.yahoo.com)
- QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements (finance.yahoo.com)
Qiagen (QGEN) traded down $0.26 during trading hours on Wednesday, hitting $31.95. 791,584 shares of the company’s stock traded hands, compared to its average volume of 1,773,071. The firm has a market capitalization of $7,440.00, a P/E ratio of 81.92, a price-to-earnings-growth ratio of 1.80 and a beta of 1.10. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. Qiagen has a fifty-two week low of $27.51 and a fifty-two week high of $36.34.
Several analysts recently weighed in on the stock. TheStreet upgraded shares of Qiagen from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Cowen reiterated a “hold” rating and issued a $34.00 target price on shares of Qiagen in a report on Thursday, December 21st. Evercore ISI assumed coverage on shares of Qiagen in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $34.63.
COPYRIGHT VIOLATION NOTICE: This story was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2018/01/10/qiagen-qgen-getting-favorable-media-coverage-study-shows.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.